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Background
The induction of potent mucosal immune responses will
be critical for an effective HIV vaccine, However, a major
limitation of current vaccine development is the ability to
induce mucosal antibodies by a systemic, non-replicating
vector. To address this inadequacy, we have hypothesized
that encoding instructions for immune cell targeting to
the mucosa in the form of MEC, a mucosal chemokine
adjuvant delivered as a plasmid can redirect immune
responses in vivo. MEC (CCL28) is normally expressed by
epithelium in the skin, lungs, and intestines and it func-
tions to attract CCR10 expressing plasmablasts locally.
Methods
IIndian rhesus macaques were vaccinated using EP deliv-
ery with either a pcon SIVmac239 gag, pol, SIVsm
unmatched E660 env vaccine delivered IM alone (n=5),
with CCL28 (MEC, n=5) or a plasmid expressed H1 HA
Influenza vaccine alone (n=4) or with MEC (n=4). SIV
Vaccinated animals and 6 naïve controls were challenged
vaginally twice weekly for four weeks with 500TCID50
SIVsmE660.
Results
The inclusion of a CCR10 ligand adjuvant enhanced vagi-
nal and serum IgG and IgA titers compared with DNA
alone. In Flu vaccinated animals functional HAI antibody
titers were significantly elevated and above the 1:40 titer
required for protection in humans with just a single dose
of H1HA delivered with the MEC adjuvant. Following
SIV challenge monkeys vaccinated with a CCR10 adju-
vant showed 89% protection from the establishment of
infection compared 40% with DNA alone with only 16%
of the naïve animals.
Conclusion
Mucosal and systemic antibody responses were
enhanced with the inclusion of a CCR10 ligand adju-
vant. Dose sparing was also observed. DNA vaccination
alone improved challenge outcome, and this was further
enhanced by the inclusion of a CCR10 ligand adjuvant.
The inclusion of mucosal homing chemokines repre-
sents a novel approach to induce improved mucosal
immune responses by non-live systemic immunization
of relevance to HIV infection.
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